monoamines disrupts the ability of flies to track the odor plume, while a rescue of octopamine signaling in these flies is sufficient to restore normal tracking.
These experiments suggest that the cross-modal odor modulation of visual motion responses is driven specifically by octopamine release onto higher-order motion sensitive neurons, rather than by modulation of input pathways such as T4/T5 neurons. Yet given prior work also implicating octopamine as a modulator of the gain of HS neurons, why does odor not lead to an increase in the response of HS neurons as seen in Hx ( Figure 1B) ? One possibility is that octopamine neurons act via more than one postsynaptic receptor pathway, differentially expressed in higher order neurons. While experimental exogenous application of octopamine might induce modulation of gain in HS neurons also, the odor-mediated release of endogenous octopamine might not be agonistic for all post-synaptic targets. Indeed, this difference between the response of Hx and Hs provides an exciting opportunity for a broader investigation of the subtle ways in which aminergic signaling might be involved in differential cross-modal interactions within the insect nervous system.
Regardless of the outcome of future work to reconcile these findings, the study by Wasserman et al. [1] provides clear evidence for a mechanism that dynamically enhances sensory perception in a contextually appropriate manner. In humans, congruent odor cues have been shown to facilitate perception of color or shape based visual cues, just as the inventors of Smell-O-Vision had hoped to exploit in their 1950s experiments in multisensory cinema. Until recently, however, no similar effect was known for motion, which is primarily processed in the visual dorsal stream, a subdivision of the cortex that shares many properties in common with the fly lobula plate [8] . Another recent study, however [9] , showed that olfaction can indeed bias visual motion perception in humans. It remains to be seen whether such cross-modal interactions in the human dorsal stream also involve aminergic modulation, as now shown in the fly.
Tumor Biology: With a Little Help from My Dying Friends
Apoptosis is an essential form of cell death underlying daily tissue regeneration. In tumor biology, apoptosis resistance is a well-established hallmark of cancer that is targeted by therapeutic approaches. A new study assigns a hitherto-underestimated function to this 'deadly friend': apoptotic cells promote tumor growth, accumulation of tumor-associated macrophages, and angiogenesis.
Kirsten Lauber 1, * and Martin Herrmann 2
Being a central opponent of cell proliferation, apoptosis plays a pivotal role in tissue homeostasis. Apoptotic cells are swiftly removed by phagocytes and stimulate woundhealing responses, along with the production of anti-inflammatory cytokines [1] . In situ, apoptotic cells are commonly associated with macrophages, which have a tissue-remodeling, angiogenesispromoting phenotype that is also known of tumor-associated macrophages (TAMs). Accumulation of TAMs has been reported to correlate with poor prognosis in various human malignancies, and the contribution of TAMs to cancer progression has been extensively explored [2] . The mechanisms orchestrating the accumulation, differentiation and polarization of TAMs are still poorly understood, but the association of intra-tumoral apoptosis, TAM accumulation, and disease aggressiveness suggests a functional interconnection [3] .
In a new study in this issue of Current Biology, Ford et al. [4] examine the impact of apoptosis on tumor cell proliferation and tumor growth in transplantation models of lymphoma and melanoma. They report that human Burkitt lymphoma cells overexpressing the anti-apoptotic proteins Bcl-2 or Bcl-x L showed significantly delayed tumor growth compared with their wild-type counterparts after transplantation into immunodeficient SCID mice. Tumor cell proliferation in vivo was strongly impaired, although basal apoptosis was reduced and proliferation in vitro was increased. These rather surprising observations suggest that inhibition of spontaneous apoptosis interferes with non-tumor cell autonomous mechanisms that favor tumor growth in vivo. Transplantation experiments with the l-Myc lymphoma model further strengthen this conclusion: depletion of apoptotic cells from the inoculum strongly attenuated tumor growth, whereas admixing of apoptotic cells greatly accelerated it.
Histologically, Bcl-2-overexpressing lymphomas displayed lower vessel density and increased HIF-1a levels, indicating that these tumors were more hypoxic than the wild-type controls [4] . The authors focused their attention on TAMs, given that they are crucial players in apoptotic cell clearance (efferocytosis), wound healing, and angiogenesis. In biopsies from human Burkitt's lymphoma, they observed a close correlation between the frequencies of apoptotic cells and TAMs. This was further corroborated in their xenograft model, where Bcl-2-or Bcl-x L -overexpressing lymphomas revealed significantly decreased numbers of TAMs correlating with reduced intra-tumoral apoptosis. Interestingly, attempts to deplete lymphoma TAMs by clodronate liposomes, which effectively ablate circulating monocytes, indicated that these TAMs did not derive from recruited circulating monocytes, but originated -at least in part -from macrophage proliferation in situ.
Lymphoma TAMs adopted an efferocytic, pro-angiogenic, and tissue-remodeling phenotype as determined by transcriptomic profiling of laser microdissected TAMs. This distinct state of activation had presumably been 'instructed' by apoptotic lymphoma cells, as observed in in vitro co-incubation assays. It was clearly different from the activation state of isolated tingible body macrophages -germinal center macrophages that have phagocytosed apoptotic B cells -suggesting that apoptotic malignant B cells promote the formation of a different macrophage phenotype than that promoted by apoptotic germinal center B cells. The lymphoma TAMs had features in common with 'alternatively activated' macrophages, including high expression of CD206 [5] , but also displayed essential differences, for instance the lack of arginase or vascular endothelial growth factor expression. Similar findings have been reported for TAMs in murine mammary tumors [6] . Since interleukin-4 (IL-4) is a key cytokine that drives the differentiation of alternatively activated macrophages, Ford et al. [4] addressed the impact of IL-4Ra signaling on tumor growth in transplanted l-Myc lymphomas. When grafted onto IL-4Ra-deficient mice, lymphomas grew with delayed kinetics, an effect that was even more pronounced when apoptotic tumor cells were depleted from the inoculum. Nevertheless, expression of crucial TAM markers was only marginally affected in mice lacking IL-4Ra. The authors conclude that apoptotic cells and host IL-4Ra signaling both support tumor growth, but via independent mechanisms.
This study provides an impressive amount of data supporting the notion that apoptotic tumor cells promote the growth of transplanted tumors. A similar enhancement of tumor progression by inoculation with a mixture of viable and irradiated tumor cells was reported over 50 years ago [7] and also recently in an allogeneic melanoma transplantation model [8] . Furthermore, Ford et al. [4] present convincing correlation analyses of intra-tumoral apoptosis, TAM accumulation, and angiogenesis ( Figure 1 ). This is in line with observations from various human malignancies, where the correlation between TAM density and poor prognosis is well acknowledged, and mechanistic evidence from preclinical studies that has established the crucial role of TAMs in cancer progression [2] .
Most intriguing and largely provocative is the causal link between tumor cell apoptosis, increased TAM accumulation, and subsequent cancer progression. This raises several interesting questions. How can apoptotic cells support the proliferation of viable cells, and which signals are involved in apoptosisdriven tumor growth? A huge repertoire of biologically active molecules is released during apoptosis, ranging from nucleotides, lipids and proteins to microvesicles. These mediators orchestrate phagocyte recruitment and stimulate efferocytosis, but they also exert other pleiotropic effects [1, 9] . Lactoferrin appears to be a promising candidate for an apoptotic-cell-derived trophic signal, since it can mediate multiple effects on living and dying tumor cells as well as on cells of the tumor microenvironment [10] ; however, its functional involvement remains to be elucidated. Interestingly, apoptosis-mediated compensatory proliferation is only observed when apoptotic and viable cells are inoculated at the same site [8] , implying that the responsible soluble factors display a rather limited operating range or that direct cell-cell contact is required.
The data presented by Ford et al. [4] suggest that the apoptosis-driven Figure 1 . Apoptosis-driven tumor progression. In wild-type lymphoma (left), spontaneously apoptosing tumor cells are engulfed by macrophages, thus polarizing them into TAMs. Lymphoma TAMs exhibit an efferocytic, pro-angiogenic, matrix-remodeling, and wound-healing phenotype, which contributes to accelerated tumor progression. In Bcl-2-expressing lymphoma (right), spontaneous apoptosis is strongly reduced: fewer TAMs are observed, tumors have a lower vessel density, and tumor progression is impaired.
promotion of tumor growth acts in a non-tumor cell autonomous manner. Apparently, accumulation and polarization of TAMs are instigated, but other cells within the tumor microenvironment may also be affected -for instance, endothelial cells. The authors report that apoptotic lymphoma cells and apoptotic germinal center B cells shift macrophage polarization in different directions. This stimulates the question of whether apoptotic malignant and apoptotic nonmalignant cells differ per se, or whether additional factors of the tumor microenvironment are important. Most tumors are exposed to metabolically challenging conditions, including hypoxia as well as acidic pH, and lactate has recently been attributed a key role in TAM polarization in murine melanoma, lung, and colon cancer [11] . Yet, the TAM phenotype described in this earlier work diverges from the lymphoma TAM type reported by Ford et al. [4] ; the observed differences presumably arise from the tumor models employed.
Other groups have provided evidence for tumor cell autonomous mechanisms of apoptosis-driven cancer progression, showing that admixing of apoptotic cells accelerated proliferation of cancer cells in vitro [8, 12] . Ford et al. [4] instead observed a decreased expansion of apoptosis-competent lymphoma in vitro. This discrepancy could stem from differences in the ratios of apoptotic to cancer cells: whereas basal apoptosis rates in lymphoma cell populations ranged from 5 to 10%, most admixing experiments were performed with a huge excess of apoptotic cells (100-500 fold). Mechanistically, prostaglandin E 2 has previously been attributed to drive tumor cell proliferation induced by apoptotic cells, and, from studies in lower model organisms, an involvement of Hedgehog signaling in apoptosisinduced proliferation is known [12] . Further analyses are warranted to characterize in detail the tumor cell autonomous trophic factors derived from apoptotic cells.
Ford et al. [4] utilized overexpression of Bcl-2 and Bcl-x L to inhibit apoptosis. However, apoptosis resistance is a well-acknowledged hallmark of cancer, and chromosomal amplification and overexpression of anti-apoptotic Bcl-2 family members -often associated with poor prognosis -have been reported for various malignancies, particularly lymphoma [13] [14] [15] . The solution to this conundrum may be a question of timing. During tumorigenesis, oncogenes like Myc are activated and promote proliferation but also cell death. Myc-induced cell death can be blocked by anti-apoptotic Bcl-2 family members, and their overexpression is well known to synergize with enforced Myc expression in lymphomagenesis [16] . Accordingly, apoptosis resistance appears to be beneficial for establishing the malignant phenotype. Later on, when the growing tumor has to acquire the capacity to organize nutrient and oxygen supply, a certain percentage of apoptotic tumor cells can obviously facilitate TAM recruitment and angiogenesis. Transplantation models cannot evaluate this hypothesis, but genetic cancer models with inducible Bcl-2 expression could dissect the kinetics of Bcl-2 requirement in different phases of tumorigenesis and tumor progression.
The observations presented by Ford et al. [4] complement other studies showing that apoptosis-inducing therapy stimulates tumor repopulation, and macrophages have been proposed to play a crucial role in this scenario [12, 17] . Conversely, Bcl-2-targeting, pro-apoptotic cancer therapy has proven to be effective in preclinical models and is currently undergoing clinical evaluation [18] . It would be worth considering the development of new therapeutic modalities that stimulate tumor cell death and simultaneously interfere with apoptosis-driven tumor repopulation. Shifting the mode of cell death towards a more immunogenic phenotype could be one approach [19] . To this end, caspase inhibition appears to be a valuable tool, since it can trigger necroptosis when applied together with a death stimulus. Nevertheless, the applicability of this approach has to be carefully evaluated because caspase inhibition could also confer therapy resistance via overall inhibition of cell death. Interfering with the process of efferocytosis might be an alternative strategy to break the causal link between apoptosis and tumor repopulation. Masking apoptotic cells with annexin A5 has been shown to impair the efferocytic uptake of apoptotic lymphoma cells [20] . However, whether this also translates into repolarization of TAMs still remains to be defined. Finally, the apoptotic-cell-derived signals that orchestrate accumulation and polarization of TAMs could open new therapeutic perspectives. In this regard, the identification of prostaglandin E 2 reanimates the discussion about cyclo-oxygenase inhibition as an adjuvant to cancer therapy.
In conclusion, promotion of tumor growth by apoptotic cells, as described by Chris Gregory's group, has been underestimated for a long time. The generality of these findings as well as the underlying molecular details require further in-depth clarification, but it is time to redefine the traditional black-and-white picture of cell death and cell proliferation in tumor biologyparticularly when thinking of novel anti-cancer therapies. 
David W. Ray
Life evolved on Earth under conditions of marked environmental oscillation: cyclical transitions from day to night. Under these conditions complex life apportioned specific activities to particular phases, for example photosynthesis during the light phase, or sleep during the dark phase. However, such adaptations were driven by internal rhythms, rather than being a mere reaction to the change in environment; i.e., a biological clock. In a recent study reported in this issue of Current Biology from Shi et al. [1] new insights have been gained into how the biological clock is controlled, and with what consequences for behavior.
The molecular basis of the circadian (circa; about, diem; day) clock has been elucidated, and the current model is of a transcriptional and translational feedback loop. This now includes many different molecular components, some of which are rhythmically expressed, or modified, and which participate in feedback loops to modulate one another's expression. The core circuit involves an activating arm provided by the bHLH-PAS transcription factor BMAL1/ARNTL, which dimerises with CLOCK, or NPAS2. The heterodimeric transcription factor activates expression of components of the repressive feedback arm of the clock, namely, PERIOD and CRYPTOCHROME.
A core requirement for the clock to work is that at least one central clock component shows a rhythmic change in abundance of activity. Indeed, both PERIOD and CRYPTOCHROME proteins shows a rhythmic oscillation. Ubiquitinylation of CRYPTOCHROME, with resulting effects on protein turnover and circadian period, has been discovered to be due to the F-box proteins Fbxl3 and Fbxl21. However, it was not thought that BMAL1 oscillation was required for core clock function, or that such a regulatory pathway existed. However, a ubiquitinylation pathway mediated by Ube3a that regulates BMAL1 abundance and affects clock function was revealed recently in vitro.
Ube3a is encoded on human chromosome 15q11-q13. This is of interest as deletions of the maternal copy of chromosome 15 in this region are causative for the complex neurodevelopmental disorder Angelman syndrome (AS). AS is characterized by a neurodevelopmental defect resulting in motor impairments, learning difficulties, epilepsy, and sleep disorders [2, 3] . There is no treatment, and management is targeted at symptom control, with most patients requiring medication to control epilepsy. AS results from genomic imprinting, as the paternal allele is imprinted, and so not expressed. Therefore, loss of the maternal allele results in loss of Ube3a expression in tissues affected by the imprinting. In AS, paternal imprinting is only seen in the brain, so loss of Ube3a expression is seen only in brain neurons, and not glia or peripheral tissues [4] . These observations suggest a fascinating mechanistic link between loss of neuronal Ube3a expression, leading to altered BMAL1 ubiquitinylation [5] and stability, and circadian disruption, leading to sleep disturbance, specifically short sleep duration and increased sleep onset latency.
In the study reported in this issue Shi et al. [1] identify a causal link between Ube3a expression and circadian rhythm in mouse models of AS. They report weakened rhythms in vivo, which is manifest by more rapid re-setting of the circadian oscillation to changes in environmental light timing, an experimental model of jet lag or shift work. Similarly, under constant light conditions the AS model animals show an accelerated decay in rhythmic behavior.
Analyses of tissue ex vivo by Shi et al. provided new insight into the causative mechanisms of AS in their model animals. While no detectable differences in circadian oscillations in peripheral tissues were seen in AS animals compared to controls, the central brain clock located in the suprachiasmatic nucleus had a
